EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vivo screening of flavonoid compounds revealed quercetin as a potential drug to improve recovery of angiostrongyliasis after albendazole treatment

Ho Yin Pekkle Lam, Yu-Ting Huang, Ting-Ruei Liang, Shih-Yi Peng iD

PLOS Neglected Tropical Diseases · 2024

DOI: 10.1371/journal.pntd.0012526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Neglected Tropical Diseases, 2024. Verfasst von Ho Yin Pekkle Lam und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, Taiwan. Hauptthemen laut MEDLINE: Albendazole, Quercetin, Strongylida Infections, Angiostrongylus cantonensis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human angiostrongyliasis, caused by consuming the larva stage of Angiostrongylus cantonensis , is an infectious disease involving the central nervous system (CNS) and ophthalmic system. Current treatment of angiostrongyliasis involves albendazole accompanied by analgesics and corticosteroids. However, long-term use of corticosteroids may lead to significant adverse effects. In the current study, we screened through different potentially effective flavonoid compounds and identified quercetin as an effective anti-inflammatory agent in an angiostrongyliasis mouse model. Our results identified that quercetin may reverse the neurological defects in mice with angiostrongyliasis. The brain pathology and inflammatory status were also improved by albendazole-quercetin co-therapy. Further analysis showed that albendazole-quercetin co-therapy had a better therapeutic effect than albendazole or quercetin monotherapy. This therapeutic effect was achieved by inhibiting the brain inflammasome activation and apoptosis. Albendazole-quercetin co-therapy also leads to the inhibition of brain IL-5, possibly leading to improved pathology. Our results here proved that quercetin may serve as a potential adjuvant drug in treating human angiostrongyliasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlbendazoleQuercetinStrongylida InfectionsAngiostrongylus cantonensisAnimalsMiceDisease Models, AnimalBrainAnthelminticsFemaleFlavonoidsAnti-Inflammatory AgentsApoptosisDrug Therapy, CombinationInflammasomesHumans

Substanzen

AlbendazoleQuercetinAnthelminticsFlavonoidsAnti-Inflammatory AgentsInflammasomes

Autor:innen und Institutionen

  • Department of Biochemistry, School of Medicine, Tzu Chi University, Hualien, Taiwan.
  • Institute of Medical Science, Tzu Chi University, Hualien, Taiwan.
  • Department of Laboratory Medicine and Biotechnology, Tzu Chi University, Hualien, Taiwan.
  • Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
  • PhD Program in Pharmacology and Toxicology, Tzu Chi University, Hualien, Taiwan.

ORCID-Profile: Shih-Yi Peng

Zitieren

APA

Lam, H. Y. P., Huang, Y. T., Liang, T. R., & Peng, S. Y. (2024). In vivo screening of flavonoid compounds revealed quercetin as a potential drug to improve recovery of angiostrongyliasis after albendazole treatment. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0012526

Vancouver

Lam HYP, Huang YT, Liang TR, Peng SY. In vivo screening of flavonoid compounds revealed quercetin as a potential drug to improve recovery of angiostrongyliasis after albendazole treatment. PLOS Neglected Tropical Diseases. 2024. doi:10.1371/journal.pntd.0012526

BibTeX
@article{Lam2024,
  author = {Lam, Ho Yin Pekkle and Huang, Yu-Ting and Liang, Ting-Ruei and Peng, Shih-Yi},
  title = {In vivo screening of flavonoid compounds revealed quercetin as a potential drug to improve recovery of angiostrongyliasis after albendazole treatment},
  journal = {PLOS Neglected Tropical Diseases},
  year = {2024},
  doi = {10.1371/journal.pntd.0012526}
}
Kostenlos starten →